HSBC has initiated coverage on Regeneron Pharmaceuticals Inc (REGN) with a Buy rating, marking the firm's first assessment of the company's investment potential. This move underscores HSBC's confidence in Regeneron's business model and growth prospects within the biotechnology sector.
Headquartered in Tarrytown, New York, Regeneron specializes in the discovery, development, and commercialization of medicines for serious diseases. The company employs over 15,000 staff and leverages proprietary technologies such as VelociSuite to accelerate drug development. Its marketed products include EYLEA, Dupixent, and Libtayo, among others.
As of November 20, 2025, Regeneron boasts a market capitalization of $73.9 billion, a P/E ratio of 16.13, and an impressive dividend yield of 50.1%. The company is expected to report earnings on July 30, 2026, with an estimated EPS of $11.68 and revenue of $3.8 billion.
Analyst ratings provide insights based on extensive research and financial models. However, these assessments reflect assumptions that may not always materialize. Investors are advised to consider multiple factors, including company fundamentals and industry trends, when making decisions. Analyst views should serve as one of many inputs in investment strategies.
It's important to note that analyst ratings can evolve with new information, and differing opinions may arise among analysts covering the same company.